...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3
【24h】

Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3

机译:对补体32的应答基因通过介导转化生长因子β诱导的人胰腺癌细胞系BxPC-3的上皮-间质转化增强转移表型

获取原文
           

摘要

Background Response gene to complement-32 (RGC-32) is comprehensively expressed in many kinds of tissues and has been reported to be expressed abnormally in different kinds of human tumors. However, the role of RGC-32 in cancer remains controversial and no reports have described the effect of RGC-32 in pancreatic cancer. The present study investigated the expression of RGC-32 in pancreatic cancer tissues and explored the role of RGC-32 in transforming growth factor-beta (TGF-β)-induced epithelial-mesenchymal transition (EMT) in human pancreatic cancer cell line BxPC-3. Methods Immunohistochemical staining of RGC-32 and E-cadherin was performed on specimens from 42 patients with pancreatic cancer, 12 with chronic pancreatitis and 8 with normal pancreas. To evaluate the role of RGC-32 in TGF-β-induced EMT in pancreatic cancer cells, BxPC-3 cells were treated with TGF-β1, and RGC-32 siRNA silencing and gene overexpression were performed as well. The mRNA expression and protein expression of RGC-32 and EMT markers such E-cadherin and vimentin were determined by quantitative reverse transcription-PCR (qRT-PCR) and western blot respectively. Finally, migration ability of BxPC-3 cells treated with TGF-β and RGC-32 siRNA transfection was examined by transwell cell migration assay. Results We found stronger expression of RGC-32 and higher abnormal expression rate of E-cadherin in pancreatic cancer tissues than those in chronic pancreatitis tissues and normal pancreatic tissues. Immunohistochemical analysis revealed that both RGC-32 positive expression and E-cadherin abnormal expression in pancreatic cancer were correlated with lymph node metastasis and TNM staging. In addition, a significant and positive correlation was found between positive expression of RGC-32 and abnormal expression of E-cadherin. Furthermore, in vitro, we found sustained TGF-β stimuli induced EMT and up-regulated RGC-32 expression in BxPC-3 cells. By means of siRNA silencing and gene overexpression, we further demonstrated that RGC-32 mediated TGF-β-induced EMT and migration in BxPC-3 cells. Conclusions The results above indicated that RGC-32 might be a novel metastasis promoting gene in pancreatic cancer and it enhances metastatic phenotype by mediating TGF-β-induced EMT in human pancreatic cancer cell line BxPC-3.
机译:背景对补体32的应答基因(RGC-32)在多种组织中全面表达,并且据报道在不同种类的人类肿瘤中异常表达。然而,RGC-32在癌症中的作用仍存在争议,尚无报道描述RGC-32在胰腺癌中的作用。本研究调查了RGC-32在胰腺癌组织中的表达,并探讨了RGC-32在转化生长因子-β(TGF-β)诱导的人胰腺癌细胞系BxPC-中的上皮-间质转化(EMT)中的作用。 3。方法对42例胰腺癌,12例慢性胰腺炎和8例正常胰腺的标本进行RGC-32和E-cadherin的免疫组织化学染色。为了评估RGC-32在TGF-β诱导的胰腺癌细胞EMT中的作用,用TGF-β1处理BxPC-3细胞,并进行RGC-32 siRNA沉默和基因过表达。分别通过定量逆转录PCR(qRT-PCR)和western blot检测RGC-32和EMT标志物如E-cadherin和波形蛋白的mRNA表达和蛋白表达。最后,通过transwell细胞迁移试验检测了用TGF-β和RGC-32 siRNA转染的BxPC-3细胞的迁移能力。结果与慢性胰腺炎组织和正常胰腺组织相比,胰腺癌组织中RGC-32的表达增强,E-钙粘蛋白的异常表达率更高。免疫组织化学分析显示,胰腺癌中RGC-32阳性表达和E-cadherin异常表达均与淋巴结转移和TNM分期有关。另外,在RGC-32的阳性表达与E-钙粘蛋白的异常表达之间发现显着且正相关。此外,在体外,我们发现持续的TGF-β刺激可诱导BxPC-3细胞中的EMT并上调RGC-32表达。通过siRNA沉默和基因过表达,我们进一步证明RGC-32介导TGF-β诱导的EMT和BxPC-3细胞迁移。结论以上结果表明RGC-32可能是胰腺癌的一个新的转移促进基因,它通过介导TGF-β诱导的人胰腺癌细胞系BxPC-3的EMT而增强转移表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号